Riccardo Lucis

Dr. Riccardo Lucis

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2025 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
ARAlberto Rizzo
Alberto Rizzo
EMEnrico Mensa
Enrico Mensa
LSLaura Squarzon
Laura Squarzon
PCPierangelo Clerici
Pierangelo Clerici
RLRiccardo Lucis
Riccardo Lucis

24 February 2025 in American Journal of Infection Control
Verified
Journal Article
Closed access
ARAlberto Rizzo
Alberto Rizzo
AVAndrea De Vito
Andrea De Vito
RLRiccardo Lucis
Riccardo Lucis
DMDavide Mileto
Davide Mileto
AGAndrea Giacomelli
Andrea Giacomelli

22 July 2026 in Therapeutic Advances in Infectious Disease
Verified
Journal Article
Open access
Daniele Roberto GiacobbeDaniele Roberto Giacobbe
Daniele Roberto Giacobbe
RLRiccardo Lucis
Riccardo Lucis
SBSuryabrata Banerjee
Suryabrata Banerjee
GCGiorgia Carra
Giorgia Carra
EDEric Dexter
Eric Dexter
ARAlberto Rizzo
Alberto Rizzo
Background: General-purpose large language model (LLM)–based systems are increasingly accessible to clinicians and are being explored for applications in clinical microbiology and infectious diseases (ID). However, rapid adoption has outpaced the development of specialty-specific guidance, raising concerns related to safety, reliability, accountability, and antimicrobial stewardship. Objectives: The project aims to develop consensus-based statements, endorsed by Study Group for Artificial Intelligence and Digitalisation of the European Society of Clinical Microbiology and Infectious Diseases (ESGAID), that describe principles, opportunities, and limitations in the interactions of clinical microbiologists and ID specialists with general-purpose LLM-based systems. Secondary objectives are to quantify expert agreement and identify areas of uncertainty and disagreement. Design: The project follows a structured expert consensus design using the RAND/UCLA Appropriateness Method. Methods and analysis: A multidisciplinary panel of 15 experts will be selected through ESGAID using predefined criteria to ensure balanced expertise across clinical microbiology, infectious diseases, ethics, legal aspects, and patient safety. Ten draft statements, each supported by a structured literature review, will be developed by project coordinators. Statements will be evaluated through iterative rounds of anonymous rating on a 1–9 scale, combined with moderated remote discussions. Median scores will classify statements as supported, uncertain, or unsupported. Consensus will be defined as ⩾70% agreement with <15% disagreement during final anonymous voting. Discussion: This protocol provides a transparent and reproducible framework to generate interim, specialty-specific statements on principles, opportunities, and limitations in the interactions of clinical microbiologists and ID specialists with general-purpose LLM-based systems. By combining structured evidence review with expert judgment, the resulting statements aim to delineate guidance on principles for interacting with these systems, highlight the nature of both existing risks and excessive skepticism, and identify research priorities in a rapidly evolving technological and regulatory landscape.

27 July 2026 in Infectious Disease Reports
Verified
Journal Article
Open access
PDF file
Francesco BrandaFrancesco Branda
Francesco Branda
LALILIA ANDRIANI
LILIA ANDRIANI
RLRiccardo Lucis
Riccardo Lucis
ADAnnamaria Defilippo
Annamaria Defilippo
ULUgo Lomoio
Ugo Lomoio
Pietro Hiram GuzziPietro Hiram Guzzi
Pietro Hiram Guzzi
Background: Accurate and timely malaria diagnosis with species-level identification of Plasmodium parasites is critical for guiding effective treatment and disease management. Although light microscopy remains the diagnostic gold standard, its dependence on highly trained personnel limits accessibility, particularly in resource-constrained settings. Recent advances in deep learning have enabled automated image-based diagnosis with promising performance; however, reliable differentiation among Plasmodium species continues to pose a major challenge. This study aims to evaluate and compare the effectiveness of different deep learning architectures for automated species identification from microscopy images. Methods: Three deep learning architectures were systematically assessed: a convolutional backbone (ResNet50), a Vision Transformer (ViT), and a hybrid ResNetViT model. All models were trained from scratch, without using pretrained weights, on a dataset comprising real-world thick blood smear images augmented with publicly available microscopy data from Kaggle. In the hybrid architecture, the ResNet module was used to extract robust local morphological features, while the ViT component captured long-range dependencies and contextual relationships within images. Results: In cross-validation experiments, all three architectures consistently achieved high diagnostic performance. ResNet50 attained the highest accuracy (96.9%), an F1-score of 96.3%, and an ROC-AUC of 0.997. The Vision Transformer achieved 93.1% accuracy, 91.7% F1-score, and an ROC-AUC of 0.989. The hybrid ResNetViT reached 95.2% accuracy, 94.2% F1-score, and an ROC-AUC of 0.995. These results confirm that all architectures can reliably distinguish among Plasmodium species. Although ResNet50 achieved the highest raw accuracy, the hybrid model showed the most stable calibration and the closest qualitative agreement between its attention maps and expert-annotated parasite locations. Conclusions: The findings demonstrate that convolutional, transformer-based, and hybrid deep learning architectures can be successfully trained on real microscopy data for species-level malaria diagnosis. These results support the feasibility of deploying scalable, automated diagnostic systems to improve both accuracy and accessibility of malaria detection, particularly in resource-limited healthcare settings.

Verified
Journal Article
Open access
PDF file
Francesco BrandaFrancesco Branda
Francesco Branda
LALILIA ANDRIANI
LILIA ANDRIANI
RLRiccardo Lucis
Riccardo Lucis
RPRiccardo Prete
Riccardo Prete
ADAnnamaria Defilippo
Annamaria Defilippo
Pietro Hiram GuzziPietro Hiram Guzzi
Pietro Hiram Guzzi
Background: Malaria continues to pose a significant global public health challenge, as reflected in the estimated 282 million cases and 610,000 associated deaths recorded worldwide in 2024. Elimination efforts are threatened by antimalarial drug resistance, relapsing Plasmodium vivax infections, and emerging zoonotic Plasmodium knowlesi. Accurate species-level identification is critical for appropriate treatment and surveillance, yet conventional microscopy is labor-intensive and operator-dependent, while rapid diagnostic tests lack sensitivity and species-discrimination capacity. This diagnostic gap underscores the need for automated, trustworthy AI-based tools. Methods: We present MalarIA, a modular, extensible AI-based web platform designed to translate deep learning research into deployable malaria diagnostics. The platform integrates three architectures, ResNet50, Vision Transformer (ViT), and a hybrid ResNetViT, that our group previously trained from scratch on 1038 real-world blood smear images spanning four Plasmodium species (P. falciparum, P. vivax, P. malariae, and P. ovale). MalarIA features a model registry for seamless integration of novel architectures, five Class Activation Mapping (CAM) variants for explainability, Expected Calibration Error (ECE) for confidence reporting, and a validation module (MalarIA Validator) supporting human-in-the-loop active learning and multicenter external validation. Results: The contribution of this article is the design and implementation of the platform itself; the predictive performance results summarized here are reused from our previous cross-validation study and no new model training is claimed in the present work. In that earlier evaluation, ResNet50 achieved the highest accuracy (96.9%, F1 96.3%, ROC-AUC 0.997, macro-averaged AUC-PR 0.990, Cohen’s kappa 0.939). The hybrid ResNetViT demonstrated superior calibration (ECE 0.0175 vs. 0.0263 for ResNet50 and 0.0778 for ViT, recomputed from the archived out-of-fold predictions) and enhanced sensitivity for minority species (P. malariae recall 0.970; P. vivax 0.978). The platform is demonstrated end-to-end through its web interface, from image upload to explainable species-level results. Conclusions: MalarIA demonstrates that translational AI, grounded in extensibility, explainability, rigorous calibration, and practical deployment, can effectively bridge the gap between research and clinical impact in malaria diagnostics. The platform is currently a research-grade prototype: the interface, model registry, explainability and calibration modules are implemented and demonstrated, while full backend model serving, multicenter validation, and regulatory assessment remain planned future developments.

23 October 2025 in NEJM AI
Verified
Journal Article
Closed access
ARAlberto Rizzo
Alberto Rizzo
EMEnrico Mensa
Enrico Mensa
DMDavide Mileto
Davide Mileto
AGAndrea Giacomelli
Andrea Giacomelli
RLRiccardo Lucis
Riccardo Lucis
DEDavid Eyre
David Eyre